ARTH Stock Overview
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Arch Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.16 |
| 52 Week High | US$18.00 |
| 52 Week Low | US$0.39 |
| Beta | 3.56 |
| 1 Month Change | -44.76% |
| 3 Month Change | -77.90% |
| 1 Year Change | -66.86% |
| 3 Year Change | -94.73% |
| 5 Year Change | -98.45% |
| Change since IPO | -98.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARTH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -27.0% | -4.1% | -3.7% |
| 1Y | -66.9% | -2.2% | 20.5% |
Return vs Industry: ARTH underperformed the US Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: ARTH underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ARTH volatility | |
|---|---|
| ARTH Average Weekly Movement | 20.4% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARTH's share price has been volatile over the past 3 months.
Volatility Over Time: ARTH's weekly volatility has decreased from 46% to 20% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 8 | Terrence Norchi | www.archtherapeutics.com |
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company’s flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds.
Arch Therapeutics, Inc. Fundamentals Summary
| ARTH fundamental statistics | |
|---|---|
| Market cap | US$4.97m |
| Earnings (TTM) | -US$7.86m |
| Revenue (TTM) | US$115.33k |
44.7x
P/S Ratio-0.7x
P/E RatioIs ARTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARTH income statement (TTM) | |
|---|---|
| Revenue | US$115.33k |
| Cost of Revenue | US$84.13k |
| Gross Profit | US$31.20k |
| Other Expenses | US$7.90m |
| Earnings | -US$7.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 27.05% |
| Net Profit Margin | -6,819.07% |
| Debt/Equity Ratio | -74.6% |
How did ARTH perform over the long term?
See historical performance and comparison